TRCT
SGNT

Tower Research Capital (TRC)’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-477
Closed -$6K – 5433
2016
Q1 		$6K Buy
+477
New +$6.69K ﹤0.01% 2623
2015
Q4 		– Sell
-224
Closed -$3K – 5555
2015
Q3 		$3K Buy
+224
New +$4.84K ﹤0.01% 3247
2014
Q4 		– Sell
-2
Closed – – 5240
2014
Q3 		$0 Sell
2
-98
-98% -$2.65K ﹤0.01% 5245
2014
Q2 		$3K Sell
100
-382
-79% -$8.48K ﹤0.01% 3301
2014
Q1 		$11K Sell
482
-304
-39% -$6.65K ﹤0.01% 2553
2013
Q4 		$20K Sell
786
-2,020
-72% -$45.6K ﹤0.01% 2362
2013
Q3 		$57K Sell
2,806
-702
-20% -$15.6K 0.01% 1798
2013
Q2 		$74K Buy
+3,508
New +$62.7K 0.01% 665

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Tower Research Capital (TRC)'s SGNT Position: Q2 2016 in Review

Tower Research Capital (TRC) sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2016, closing a stake of 477 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in SGNT in Q2 2013 and held it in 8 quarters. The position peaked at $74K in Q2 2013. 128 funds tracked by Wall St. Rank hold SGNT as of Q2 2016.

  • Tower Research Capital (TRC) reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 477 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2016, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $74K in Q2 2013.
  • 128 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2016, filed 10 Aug 2016.